

Megan Wind-Rotolo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1467950/publications.pdf>

Version: 2024-02-01

17
papers

5,281
citations

759055

12
h-index

1058333

14
g-index

17
all docs

17
docs citations

17
times ranked

7541
citing authors

#	ARTICLE	IF	CITATIONS
1	HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. <i>Lancet Oncology</i> , The, 2022, 23, 172-184.	5.1	58
2	Soluble PD-L1 as an early marker of progressive disease on nivolumab. , 2022, 10, e003527.		35
3	Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. , 2022, 10, e004316.		45
4	Misannotated Multi-Nucleotide Variants in Public Cancer Genomics Datasets Lead to Inaccurate Mutation Calls with Significant Implications. <i>Cancer Research</i> , 2021, 81, 282-288.	0.4	7
5	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1371-1380.	3.2	49
6	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. <i>Nature Communications</i> , 2021, 12, 808.	5.8	84
7	Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC. , 2021, 9, e001506.		23
8	Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing. <i>Clinical Cancer Research</i> , 2021, 27, 4287-4300.	3.2	42
9	TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. <i>Cancer Immunology Research</i> , 2021, 9, 1202-1213.	1.6	71
10	A Machine Learning Approach to Identify a Prognostic Cytokine Signature That Is Associated With Nivolumab Clearance in Patients With Advanced Melanoma. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 978-987.	2.3	23
11	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. <i>Nature Medicine</i> , 2020, 26, 909-918.	15.2	488
12	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 2174-2184.	3.2	80
13	Abstract CT037: Genomic analyses and immunotherapy in advanced melanoma. <i>Cancer Research</i> , 2019, 79, CT037-CT037.	0.4	16
14	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. <i>Science</i> , 2018, 359, 801-806.	6.0	898
15	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 378, 1277-1290.	13.9	3,334
16	The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies. <i>European Journal of Cancer</i> , 2018, 103, 259-266.	1.3	13
17	FRACTION (Fast Real-time Assessment of Combination Therapies in Immuno-Oncology)-gastric cancer (GC): A randomized, open-label, adaptive, phase 2 study of nivolumab in combination with other immuno-oncology (IO) agents in patients with advanced GC.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4137-TPS4137.	0.8	15